Risk factors belonging to the babies in whom hearing deficit was found [less than or equal to] 32 > 32 GW GW(n=49) (n=122) Aminoglycoside or 49 50 glycopeptide
Hyperbilirubinemia 47 27 Sepsis 36 15 Respiratory distress syndrome 45 - Mechanical ventilator 26 11 Furosemide 11 16 Intrauterine growth failure 12 12 Mutiple pregnancy 14 8 Congenital anomaly 1 18 Chronic lumg disease 11 - Operation for retinopathy of prematurity 8 - Exhange transfusion 3 4 Hypoglycemia - 2 Total (n=171) Aminoglycoside or 99 (57.
Adverse events associated with neonatal exchange transfusion for
hyperbilirubinemia.
Several studies have found that the late-preterm population is at risk for respiratory complications,
hyperbilirubinemia, poor feeding and hypoglycemia, temperature instability, and infection.
Hyperbilirubinemia has been recognized as the most common cause of readmission of healthy newborns after early hospital discharge.
Higher-severity acute adverse events were uncommon and consisted of single cases of diarrhea and
hyperbilirubinemia.
Efficacy of phototherapy in prevention and management of neonatal
hyperbilirubinemia.
They address genetics, biochemistry, transport, metabolism of bilirubin, the physiology and epidemiology of neonatal
hyperbilirubinemia, public policy measures, clinical management, and interventions for the prevention and treatment of
hyperbilirubinemia and bilirubin encephalopathy in low and middle-income countries.
Q Our neonatologist is interested in screening for glucose-6-phosphate dehydrogenase (G6PD) for the evaluation of
hyperbilirubinemia of newborns.
A large number of admissions in the neonatal intensive care unit are due to neonatal
hyperbilirubinemia with a concern that due to immaturity of blood brain barrier these infants are at a risk of developing neonatal encephalopathy3.
However, treating mild gestational diabetes did not improve the composite primary outcome of neonatal mortality, hypoglycemia,
hyperbilirubinemia, hyperinsulinemia, and birth trauma in a multicenter, randomized trial designed to establish whether such treatment reduced perinatal and obstetric complications.
Researchers at UCSF Children's Hospital and Kaiser Permanente's Division of Research in Oakland, CA, claim that their study is the firs to examine the effectiveness of universal screening for
hyperbilirubinemia.
drug is expected to become the first and only pharmacologic option in the US indicated for treatment of neonates at risk for developing severe
hyperbilirubinemia, or severe jaundice.
